Marcia P. Belvin, Ph.D.

Marcia P. Belvin, Ph.D.

Senior Vice President, and Chief Scientific OfficeratCytomX Therapeutics· In the 2023 proxy

Pay in FY2023CytomX Therapeutics stock -3.1% the same year

Marcia P. Belvin, Ph.D. was paid $1.2M in FY2023 (Dec). CytomX Therapeutics stock fell 3.1% that year.

Pay$100 in the stock at the end of FY22 → $97
Pay is from the Summary Compensation Table of each CytomX Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. CytomX TherapeuticsPublic company · 3 yr
    • Senior Vice President, and Chief Scientific Officer2023 – Present · 3 yrStock in role +63%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?